All In Biotech

Drug Trial Radar · NCT01034774

Phase 1 Study to Determine Safety, Blood PK and Lung Penetration

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) ACHN-490 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Feb 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 2010

Primary completion

Jun 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Multiple center, double-blind, randomized, placebo-controlled study to see if it is safe to give ACHN-490 Injection for 5 consecutive days, to measure plasma pharmacokinetics, and to determine lung penetration of ACHN-490 (measured in ELF-epithelial lining fluid)after a single dose of ACHN-490 Injection in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • ACHN-490 InjectionDrug

    ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.

  • Placebo (normal saline)Drug

    Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety measured by reported adverse events after administering ACHN-490 Injection/placebo for 5 consecutive daysTime frame: Throughout the study

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.